A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-21. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
=== Two-dimensional chromatography === Two-dimensional chromatography represents the most thorough and rigorous approach to evaluation of the proteome. While previously accepted approaches have utilized elution mode chromatographic approaches such as cation exchange to reversed phase HPLC, yields are typically very low requiring analytical sensitivities in the picomolar to femtomolar range. As displacement chromatography offers the advantage of concentration of trace components, two dimensional chromatography utilizing displacement rather than elution mode in the upstream chromatography step represents a potentially powerful tool for analysis of trace components, modifications, and identification of minor expressed components of the proteome.
Bacterial infections may be treated with antibiotics, which are classified as bacteriocidal if they kill bacteria or bacteriostatic if they just prevent bacterial growth. There are many types of antibiotics, and each class inhibits a process that is different in the pathogen from that found in the host. An example of how antibiotics produce selective toxicity are chloramphenicol and puromycin, which inhibit the bacterial ribosome, but not the structurally different eukaryotic ribosome. Antibiotics are used both in treating human disease and in intensive farming to promote animal growth, where they may be contributing to the rapid development of antibiotic resistance in bacterial populations. Infections can be prevented by antiseptic measures such as sterilising the skin prior to piercing it with the needle of a syringe, and by proper care of indwelling catheters. Surgical and dental instruments are also sterilised to prevent contamination by bacteria. Disinfectants such as bleach are used to kill bacteria or other pathogens on surfaces to prevent contamination and further reduce the risk of infection.
== Drawbacks == In SEC, mass is not measured so much as the hydrodynamic volume. Themolecular weight can be approximated from SEC data by the relationship between molecular weight and hydrodynamic volume for polystyrene standards. Another drawback is the possibility of interaction between the stationary phase and the analyte. Any interaction leads to a later elution time and thus mimics a smaller analyte size. Band broadening occura by turbulence, thermal diffusion, and friction. Bands also overlap with each other. As a result, the eluent usually gets considerably diluted. A few precautions can be taken to prevent the likelihood of the bands broadening. For instance, one can apply the sample in a narrow, highly concentrated band on the top of the column. The more concentrated the eluent is, the more efficient the procedure would be.
== Terminology and definition == The term fungarium was introduced by Brian Spooner and Paul Cannon and presented by David Hawksworth in 2010 as a logical analogue to herbarium for collections of preserved fungi. Historically, mycology was treated as a sub-discipline of botany, so fungal specimens were commonly stored within herbaria. The proposal of fungarium formed part of a broader assertion of mycological independence; a related development is the use of "funga" for the fungi of a particular area, in parallel with "flora" for plants and "fauna" for animals. Hawksworth recommended fungarium for facilities whose taxonomic value centres on representative members of the Fungi, although many institutions have continued to use "herbarium" for historical reasons or for combined botanical-mycological collections. The term gained wider professional use when the Royal Botanic Gardens, Kew adopted it for its mycological collection. While some institutions use the term to explicitly distinguish mycological holdings from plant collections, others maintain the name "herbarium" for historical continuity. Similarly, the term "lichenarium" is occasionally used by institutions that maintain separate collections of lichen specimens. In scientific usage, a fungarium is centred on preserved fungal material, usually dried tissue such as whole reproductive structures or representative parts, though it may also include permanent microscope slides and, more rarely, specimens preserved in liquid.
HITS-CLIP (High-throughput sequencing of RNA isolated by crosslinking immunoprecipitation or CLIP-seq) PAR-CLIP (Photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation) iCLIP (Individual nucleotide-resolution cross-linking and immunoprecipitation) eCLIP (Enhanced cross-linking and immunoprecipitation followed by high-throughput sequencing) sCLIP (Simple cross-linking and immunoprecipitation)
Sources: en.wikipedia.org
=== Kwabena Bannerman === Kwabena Bannerman (Toheeb Jimoh) is an associate trader of Ghanaian descent working for Harper’s short-only fund at Mostyn Asset Management. He and Harper are casually involved, though his laidback temperament contrasts with her intensity and single-minded focus on the business. During her controversial short of porn aggregator Siren, Harper has Kwabena draft a forceful email to investors denying redemption requests. She later recruits him to join her new fund, SternTao, but liquidates his other positions to meet a margin call from Deutsche Bank. Kwabena travels to Accra with Sweetpea to investigate Tender’s operations; using family connections, he secures a meeting that helps them uncover falsified profits and recycled revenue at a local payment processor Tender had acquired. Harper presents their findings at an investment conference, triggering a 28% drop in Tender’s stock. The Tender short ultimately nets £110 million, with Harper, Sweetpea, and Kwabena distributing £2 million each and scouting a new office for the fund. Kwabena accompanies Harper to Paris for a political fundraiser hosted by Yasmin but skips the dinner and later admits to Harper that he danced intimately with another woman that night and felt no guilt, questioning the emotional detachment in their relationship and her refusal to confront him about sleeping with Sweetpea. Harper acknowledges she avoids intimacy as self-protection, while Kwabena argues that isolating herself from those closest to her comes at too high a cost.
In May of 1893, Wilmot Castle & Company began the production of modified versions of the Arnold Steam Sterilizer designed for the sterilization of baby bottles and pasteurization of cow's milk. The original sterilizer was based on William E, Arnold's Arnold Steam Cooker first patented in 1879. The Sterilizer and Pasteurizer began playing a significant role in pediatric hospital settings throughout the United States. In 1903, researchers documented the Arnold Sterilizer's effectiveness in battling Cholera Infantum. This was caused primarily by contaminated cow's milk resulting in summer-time infant mortality in Boston's slums and across the country. By 1914 the Castle Home Pasteurizer was available for families and written up in Good Housekeeping Magazine. Allen and Hanbury introduced a new bottle design with a removable valve and teat on the two ends in 1894, and an improved model, the Allenbury, in 1900. This "banana" bottle was easier to clean. Sometimes referred to as the "hygienic bottle", it helped to improve survival rates. Similar bottles were introduced by other manufacturers and remained popular from the 1900s to the 1950s. Eventually increased understanding of the causes and transmission of disease and improvements in medicine and public health began to reduce infant mortality. Heat-resistant Pyrex bottles were introduced to the American and British markets at different times. Pyrex bottles were first introduced in the United States by Corning Inc. in 1922.
== Structure == This membrane enzyme forms homodimers, partly separated by an internal ~9-Å-wide channel. The metallo beta-lactamase protein fold is adapted to associate with membrane phospholipids. A hydrophobic cavity provides an entry way for the substrate NAPE into the active site, where a binuclear zinc center catalyzes its hydrolysis. Bile acids bind with high affinity to selective pockets in this cavity, enhancing dimer assembly and enabling catalysis. NAPE-PLD facilitates crosstalk between bile acid signals and lipid amide signals.
Serine /ˈsɪəriːn/ (symbol Ser or S) is an α-amino acid that is used in the biosynthesis of proteins. It contains an α-amino group (which is in the protonated −NH+3 form under biological conditions), a carboxyl group (which is in the deprotonated −COO− form under biological conditions), and a side chain consisting of a hydroxymethyl group, classifying it as a polar amino acid. It can be synthesized in the human body under normal physiological circumstances, making it a nonessential amino acid. It is encoded by the codons UCU, UCC, UCA, UCG, AGU and AGC.
Metrohm was founded in 1943 in Herisau by Bertold Suhner and Willi Studer. At the outset, the company produced measuring instruments for high-frequency technology and telecommunications. High-precision measuring instruments as well as radio receivers were added to its product range later on. After World War II, the company struggled as the demand for their products decreased, since it was cheaper to buy imported radios from the US. Thus, Suhner decided to venture into analytical chemistry and developed a first pH meter in 1947, followed by a titrator in 1949. In 1947, Suhner and Studer parted ways. Swiss journalist and author Peter Holenstein describes how this happened in his book on the lifework of co-founder Willi Studer: In June 1947, Emil Haefely, founder of the company Emil Haefely & Cie AG, which was one of Metrohm's first customers, asked Willi Studer, whom he had known for many years, to build a prototype for a cathode-ray oscilloscope. This being new technology for Metrohm, Bertold Suhner opposed the idea, fearing that the development wouldn't be possible within reasonable time and budget constraints. Indeed, while the development of the simpler instruments in Metrohm's portfolio had never taken Studer more than a few weeks, Studer still hadn't finished the prototype after several months at the end of November 1947. At this point, his colleague Suhner lost all hope that the project would come to a successful conclusion. A break between the co-founders was the result, and led Studer to leave the company at the end of December 1947.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.